Phase I/II, Open-Label Trial of Three Monoclonal Antibodies

Inclusion Criteria

• •Laboratory values
• •Absolute neutrophil count (ANC) equal to or greter than 750/mm3.
• •Hemoglobin equal to or greater than 9.5 g/dL.
• •Platelet count equal to or greater than 50,000/mm3.
• •Calculated creatinine clearance (CrCl) equal to or greater than 80 mL/min according to the Cockcroft-Gault formula:
• •Men: (140-age in years) x (wt in kg) = CrCl (mL/min) 72 x (serum creatinine in mg/dL)
• •Female: (140-age in years) x (wt in kg) x 0.85 = CrCl (mL/min) 72 x (serum creatinine in mg/dL)
• •AST (SGOT), ALT (SGPT), and alkaline phosphatase equal to or less than 5 x ULN.
• •Total bilirubin equal to or less than 2.5 x ULN.
• •Serum Lipase equal to or less than 1.5 x ULN
• •Negative serum pregnancy test within 14 days. All females of childbearing potential must agree to practice active birth control measures (barrier methods such as condoms, diaphragms, cervical cap, etc. or an intrauterine device such as a coil) to avoid pregnancy while receiving the study drugs and for 30 days after the last dose of the study drugs. Additionally, men enrolled in the study should practice active birth control for the same period of time with their female partners of childbearing potential.
• •Men and women age \>18 years. Ability and willingness of subject to give written informed consent -